/Mckesson%20Corporation%20logo%20on%20phone-by%20IgorGolovniov%20via%20Shutterstock.jpg)
Headquartered in Irving, Texas, McKesson Corporation (MCK) stands as one of the most influential players in global healthcare distribution. The company moves pharmaceuticals, medical-surgical supplies, and critical health products across a vast network that links biopharma manufacturers, providers, pharmacies, and ultimately patients.
With a market cap of nearly $120.9 billion, it occupies the “large-cap” arena reserved for companies valued above $10 billion. The scale underscores its dominant position in healthcare distribution and its broad operational reach across domestic and international markets.
MCK stock currently sits at its 52-week high of $987.37, reached in February. Over the past three months, the shares have gained 11.7%, while the Nasdaq Composite ($NASX) fell 2.4%, marking clear short-term outperformance against the broader index.
The longer-term trend reinforces the strength. Over the past 52 weeks, MCK stock has surged 59% and remains up 20.4% year-to-date (YTD). During the same 52-week stretch, Nasdaq advanced 22.2% but has declined 2.5% YTD. Across both time horizons, McKesson delivered clear relative outperformance.
The technical structure supports the narrative. Since February, the stock has been trading above its 50-day moving average of $865.65. It also remains above its 200-day moving average of $776.06 since April 2025.
On Feb. 5, MCK stock climbed 16.5% following the release of fiscal Q3 2026 results a day earlier. During the quarter, revenue reached $106.2 billion, matching analyst expectations and marking an 11.4% year-over-year expansion. Adjusted EPS rose 16.3% to $9.34, surpassing the Street's estimate of $9.27.
Growth stemmed from strong oncology performance, expanding biopharma services, and continued momentum in North American pharmaceutical distribution. Management reinforced that confidence by raising its full-year non-GAAP earnings outlook, projecting 17% to 19% growth compared to the prior year.
To frame McKesson’s performance in context, rival Cencora, Inc. (COR) has gained 49.5% over the past 52 weeks and stands up 10.2% YTD. While Cencora has delivered impressive returns, McKesson has edged ahead on both longer-term and YTD measures.
Wall Street’s conviction reflects the distinction. MCK stock carries a “Strong Buy” overall rating from 17 analysts. Moreover, it is already trading above its mean price target of $973.19.
